查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1996599

患者來源異質骨移植（PDX）模型市場：按類型、腫瘤類型、研究類型、移植方法、應用和最終用戶分類－2026-2032年全球市場預測

Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Study Type, Implantation Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，患者來源異質骨移植(PDX) 模型市場價值將達到 5.9744 億美元，到 2026 年將成長至 6.7851 億美元，到 2032 年將達到 15.9133 億美元，年複合成長率為 15.02%。

主要市場統計數據
基準年 2025 5.9744億美元
預計年份：2026年 6.7851億美元
預測年份：2032年 1,591,330,000 美元
複合年成長率 (%) 15.02%

這是一本權威的關於患者來源異種移植 (PDX) 模型、其轉化意義及其在臨床前腫瘤學研究中不斷演變的作用的入門書籍。

患者來源的異種移植（PDX）模型在轉化腫瘤學中日益重要，因為它們能夠保留患者腫瘤的結構、細胞異質性以及與相關微環境的相互作用——這些特性在傳統細胞株中往往會丟失。透過將新鮮的人類腫瘤組織塊移植到免疫力缺乏的囓齒動物體內，研究人員可以獲得更真實反映臨床疾病的模型，保留分子特徵和藥物反應模式。這種高度的逼真性使其在藥物療效測試、作用機制研究和生物標記開發中效用，從而彌合了臨床前研究與臨床假設之間的差距。

從先進的分子分析到新型移植技術和協作資料框架：正在重塑 PDX 生態系統的技術和策略轉折點。

在技​​術創新和學術界、生物製藥公司以及受託研究機構(CRO) 之間戰略重點轉變的共同推動下，PDX 領域正經歷著一場變革。高解析度分子工具，例如單細胞定序和全面的基因組分析，現已常規應用於 PDX 隊列，使研究人員能夠詳細分析腫瘤內異質性並追蹤傳代抗藥性亞克隆。同時，基因組工程和人源化免疫系統模型正在拓展 PDX 模型檢驗的生物學背景，尤其是在免疫腫瘤學應用領域。

2025 年美國實施的關稅將如何改變整個臨床前生態系統的 PDX 供應鏈、採購經濟和策略採購決策？

2025年實施的關稅環境為依賴全球供應鏈維持其PDX計畫的機構帶來了新的營運考量。進口實驗室設備、專用耗材和某些動物品系的到貨成本關稅增加，加速了採購審查進程，並促使許多機構重新評估籌資策略。為此，調查團隊和採購負責人正在重新評估外部供應商的總擁有成本（TCO），並加強對前置作業時間和清關相關波動性的審查。

針對不同模型類型、腫瘤類別、診斷方法、移植方法和最終用戶需求，細分市場的具體表現和策略挑戰。

對細分市場的詳細分析表明，不同模型類型、腫瘤分類、研究方法、移植途徑、應用領域和最終用戶的需求和性能因素各不相同。小鼠和大鼠模型之間的差異會影響實驗設計，具體體現在移植存活率、免疫相容性以及對特定外科手術或原位移植的適用性等方面，從而決定療效和轉移試驗的選擇標準。胃腸道、婦科、血液系統、呼吸系統和泌尿系統等不同腫瘤類別的異質性會影響檢體的可用性、移植存活傾向以及解讀轉化訊號所需的分子註釋程度。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和競爭地位正在影響進入、監管和研究夥伴關係。

區域趨勢對PDX資源的取得、監管預期和合作研究網路有顯著影響。美洲地區在轉化腫瘤學專業知識方面特別集中，學術機構和生技公司之間形成了緊密的網路。此外，該地區也十分注重將PDX模型整合到臨床轉化流程中。這種環境使得臨床前訊號傳導和早期臨床試驗之間能夠快速迭代，同時也推動了對可靠的分子註釋和高品質生物檢體的需求。

對企業定位、合作模式與能力的投資，決定了PDX模式細分市場中各相關人員之間的競爭優勢。

在PDX（病患來源異種移植）研究領域，各機構之間的競爭格局日益受到能力廣度、分子註釋深度以及提供端到端轉化服務能力的影響。領先的供應商和機構計畫正在投資於整合生物銀行、基因組表徵和縱向體內試驗的綜合服務，以縮短藥物研發者的決策週期。學術機構與私人實驗室之間的策略夥伴關係，在擴大獲取註釋豐富的隊列資料的同時，也分擔了模型維護的成本和營運負擔。

產業領導者正在採取切實有效的措施，以增強供應鏈韌性，加速轉化價值，並最佳化臨床前測試結果。

產業領導者可以採取以下幾個具體措施來增強轉換應用的影響力和營運韌性。首先，優先投資國內族群管理和冷凍保存基礎設施，以減少跨境干擾的風險，同時維持遺傳完整性。其次，建立統一的組織獲取、移植和分子表徵流程，以提高可重複性並實現有意義的隊列間通訊協定。第三，將全面的基因組和單細胞分析整合到基準表徵工作流程中，以便基於分子層次的見解來解讀體內訊號。

為了確保分析的嚴謹性，我們採用了一種透明的跨學科研究方法，結合了與主要相關人員的訪談、技術檢驗和結構化證據整合。

本研究採用跨學科調查方法，整合了來自同行評審文獻、通訊協定庫以及對轉化科學家、實驗室主任、採購專家和合約研究組織（CRO）高管的結構化訪談的證據。主要數據透過半結構化訪談收集，以了解實際運作、挑戰和策略重點，並將這些定性研究結果與技術出版物和程序標準進行檢驗對，以確保科學準確性。

從科學、營運和政策因素中綜合洞察，這將決定 PDX舉措的短期軌跡和轉化成功。

總之，當患者來源的異種移植模型被整合到嚴謹的分子表徵流程中並透過健全的運作系統進行管理時，它們仍然是轉化腫瘤學的基石。單細胞分析、免疫人源化和原位建模的科學進步正在提高PDX平台的轉化保真度，而供應鏈壓力和採購經濟的變化正在促使國內能力建設和區域夥伴關係進行策略調整。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 病人異質骨移植（PDX）模型市場：按類型分類

  • 小鼠模型
  • 大鼠模型

第9章：病人異質骨移植（PDX）模型市場：依腫瘤類型分類

  • 消化器官系統
  • 婦科
  • 血液學
  • 呼吸系統
  • 泌尿器官系統

第10章：病患異質骨移植（PDX）模型市場：依研究類型分類

  • Ex-vivo
  • In-vitro
  • In-vivo

第11章 病人來源異質骨移植（PDX）模型市場：依移植方法分類

  • 異位
  • 同域
  • 皮下

第12章 病人異質骨移植（PDX）模型市場：依應用領域分類

  • 癌症基礎調查
  • 生物標記發現
  • 基因組和分子研究
  • 個人化醫療
  • 臨床前藥物評價
  • 腫瘤微環境分析

第13章 病患來源異質骨移植移植（PDX）模型市場：依最終使用者分類

  • 學術研究機構
  • 癌症研究中心
  • 製藥和生物技術公司

第14章 病人異質骨移植（PDX）模型市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：病患異質骨移植（PDX）模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 病人異質骨移植（PDX）模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國病患異質骨移植（PDX）模型市場

第18章：中國病人來源異質骨移植（PDX）模型市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai BIoTech, Ltd
  • Mediford Corporation by PHC Holdings Corporation
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market was valued at USD 597.44 million in 2025 and is projected to grow to USD 678.51 million in 2026, with a CAGR of 15.02%, reaching USD 1,591.33 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 597.44 million
Estimated Year [2026] USD 678.51 million
Forecast Year [2032] USD 1,591.33 million
CAGR (%) 15.02%

An authoritative primer on patient-derived xenograft (PDX) models, their translational relevance, and evolving role in preclinical oncology research

Patient-derived xenograft models are increasingly central to translational oncology as they preserve patient tumor architecture, cellular heterogeneity, and relevant microenvironmental interactions that are often lost in long-established cell lines. By engrafting fresh human tumor fragments into immunocompromised rodents, researchers obtain models that retain molecular signatures and drug response patterns more representative of clinical disease. This fidelity underpins their utility across drug efficacy testing, mechanism-of-action studies, and biomarker development, providing a bridge between preclinical exploration and clinical hypotheses.

Despite their strengths, PDX platforms present distinct operational and scientific challenges. Engraftment success varies by tumor type and specimen quality, requiring refined tissue handling, optimized implantation methods, and rigorous quality-control genotyping to guard against drift. Moreover, ethical considerations and regulatory oversight demand traceability of human-derived materials and adherence to humane animal care standards. Consequently, multidisciplinary workflows that integrate surgical retrieval, pathology review, molecular profiling, and animal husbandry are essential to realize the translational promise of PDX systems.

As the field advances, investigators must balance the high biological relevance of PDX with cost, throughput, and reproducibility constraints. The most impactful programs are those that combine standardized protocols with deep molecular annotation, enabling controlled comparisons across cohorts and accelerating the translation of preclinical signals into actionable clinical strategies.

Technical and strategic inflection points reshaping the PDX ecosystem from advanced molecular profiling to novel engraftment techniques and collaborative data frameworks

The PDX landscape is undergoing transformative shifts driven by converging technological innovations and changing strategic priorities across academia, biopharma, and contract research organizations. High-resolution molecular tools such as single-cell sequencing and comprehensive genomic profiling are now routinely layered onto PDX cohorts, enabling researchers to dissect intratumoral heterogeneity and trace resistant subclones across passages. Concurrently, genome engineering and humanized immune system models are expanding the biological contexts in which PDX models can be interrogated, particularly for immuno-oncology applications.

Operationally, there is a pronounced move from isolated in-house programs toward integrated platforms that combine biobanking, molecular characterization, and longitudinal in vivo testing. This integration is reinforced by increased demand for orthotopic engraftment and sophisticated implantation strategies that better recapitulate tumor-stroma interactions and metastatic behavior. Equally important, digital infrastructure and data-sharing frameworks are maturing, allowing comparative analyses across institutions and enabling federated approaches to cohort discovery.

Together, these shifts amplify the translational value of PDX models while reshaping service models, partnership structures, and competitive dynamics. Organizations that align technical rigor with interoperable data practices and targeted clinical translation pathways will define the next generation of preclinical de-risking strategies.

How recent United States tariffs in 2025 are altering PDX supply chains, procurement economics, and strategic sourcing decisions across the preclinical ecosystem

The tariff environment introduced in 2025 has created a new set of operational considerations for organizations that rely on global supply chains to maintain PDX programs. Tariff-driven increases in the landed cost of imported laboratory equipment, specialized consumables, and certain animal strains have accelerated procurement reviews and prompted many groups to reevaluate sourcing strategies. In response, research teams and procurement specialists are reassessing the total cost of ownership for external suppliers and increasing scrutiny of lead times and customs-related variability.

Consequently, some institutions are accelerating investments in domestic breeding and cryopreservation capacity to reduce exposure to cross-border tariffs and logistic disruptions. This nearshoring trend enhances control over genetic integrity and colony health, but it requires capital allocation, expanded facility capability, and operational expertise. At the same time, there are emerging opportunities for regional vendors that can offer validated alternatives to previously imported reagents and equipment, enabling laboratories to maintain experimental continuity while managing procurement risk.

Practically, the tariff landscape has also intensified collaboration between legal, regulatory, and procurement teams to ensure compliance while preserving scientific timelines. For multinational studies and cross-border collaborations, partners are increasingly negotiating shared risk protocols and contingency plans to mitigate the operational impact of tariff-related delays and price volatility. Ultimately, the cumulative effect is a reorientation toward supply chain resilience, strategic inventory management, and strengthened supplier qualification protocols.

Segment-specific performance and strategic imperatives across model types, tumor categories, study modalities, implantation approaches and end-user demands

A granular view of segmentation reveals differentiated needs and performance drivers across types of models, tumor classes, study modalities, implantation approaches, applications, and end users. Model type distinctions between Mice Models and Rat Models shape experimental design through differences in engraftment rates, immune compatibility, and suitability for specific surgical or orthotopic procedures, thereby informing selection criteria for efficacy or metastasis studies. Tumor heterogeneity across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological categories influences specimen availability, engraftment propensity, and the degree of molecular annotation required to interpret translational signals.

Study type choices among Ex-vivo, In-vitro, and In-vivo modalities determine how PDX resources are leveraged: ex-vivo and in-vitro assays complement in-vivo efficacy testing by enabling mechanistic interrogation and medium-throughput screening, while in-vivo studies remain essential for pharmacokinetic and tumor microenvironment assessments. Implantation method selection-whether Heterotopic, Orthotopic, or Subcutaneous-directly impacts translational relevance and throughput considerations; orthotopic approaches often yield more clinically relevant metastatic and microenvironmental phenotypes, while subcutaneous implants can offer higher throughput and standardized measurement.

Applications span Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis, each imposing unique data, annotation, and sample handling requirements. Finally, end users such as Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies bring divergent priorities around throughput, regulatory traceability, and commercial confidentiality, which in turn shape service models and partnership structures across the ecosystem.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa and Asia-Pacific influencing access, regulation and research partnerships

Regional dynamics are exerting a strong influence on access to PDX resources, regulatory expectations, and collaborative networks. In the Americas, there is significant concentration of translational oncology expertise, dense networks of academic centers and biotechs, and a pragmatic focus on integrating PDX models into clinical translational pipelines. This environment supports fast iteration between preclinical signals and early-phase clinical testing, while simultaneously driving demand for robust molecular annotation and high-quality biobanked specimens.

Europe, Middle East & Africa feature a heterogeneous regulatory landscape and a broad range of public research infrastructures. Pan-regional collaborations and consortia are common mechanisms to harmonize standards for human tissue use and animal welfare, and to pool rare tumor resources. These partnerships often prioritize standardized operating procedures and cross-site validation to enable multi-center preclinical programs with higher external validity.

The Asia-Pacific region combines rapid capacity expansion with growing domestic suppliers of laboratory equipment and animal models. Investment in local breeding facilities, coupled with strong clinical research activity in specific oncology indications, positions the region as both a market for services and a source of novel patient-derived material. Across all regions, regulatory alignment, data interoperability, and supplier qualification remain critical enablers of reproducible and translatable PDX-based research.

Corporate positioning, partnership patterns, and capability investments that define competitive advantage among stakeholders in the PDX model landscape

Competitive dynamics among organizations involved in PDX research are increasingly shaped by capability breadth, depth of molecular annotation, and the ability to offer end-to-end translational services. Leading providers and institutional programs are investing in integrated offerings that combine biobanking, genomic characterization, and longitudinal in vivo testing to shorten decision cycles for drug developers. Strategic partnerships between academic centers and commercial laboratories are expanding access to richly annotated cohorts while distributing the cost and operational burden of model maintenance.

Another salient trend is the prioritization of data assets. Entities that can aggregate interoperable molecular, phenotypic, and treatment-response datasets create differentiated value by enabling comparative analyses and predictive modeling. At the same time, organizations that demonstrate rigorous quality-control pipelines and transparent provenance for human-derived materials secure trust from regulatory and ethical oversight bodies, which is increasingly material in commercial collaborations. Additionally, vendors that offer scalable orthotopic modeling, immune humanization, or specialized implantation expertise are carving niche positions that align with specific therapeutic modalities, such as immuno-oncology or metastasis-focused programs.

Collectively, these strategic moves underscore that competitive advantage in the PDX domain accrues to those who combine scientific rigor with operational scalability and robust data stewardship.

Practical, high-impact actions for industry leaders to strengthen supply resilience, accelerate translational value and optimize preclinical study outcomes

Industry leaders can take several concrete steps to enhance translational impact and operational resilience. First, prioritize investments in domestic colony management and cryopreservation infrastructure to reduce exposure to cross-border disruptions while preserving genetic fidelity. Second, institutionalize harmonized protocols for tissue procurement, implantation, and molecular characterization to improve reproducibility and enable meaningful cross-cohort comparisons. Third, integrate comprehensive genomic and single-cell profiling into baseline characterization workflows so that in vivo signals can be interpreted in a molecularly informed context.

Fourth, cultivate strategic partnerships with specialized providers to access orthotopic and humanized model expertise without bearing full capital and operational overhead. Fifth, adopt federated data architectures and standardized metadata schemas to facilitate secure data sharing and comparative analyses across institutions. Sixth, engage proactively with regulatory and ethical authorities to shape pragmatic frameworks for human tissue use and animal welfare that support translational research while meeting compliance obligations. Finally, align commercial models to support translational endpoints-offering bundled services that encompass biobanking, molecular annotation, in vivo testing, and data delivery-to reduce friction for end-users and accelerate decision-making.

Transparent multidisciplinary research approach integrating primary stakeholder interviews, technical validation, and structured evidence synthesis to ensure analytic rigor

This research synthesis is grounded in a multidisciplinary methodology that triangulates evidence from peer-reviewed literature, protocol repositories, and structured interviews with translational scientists, lab directors, procurement specialists, and CRO executives. Primary data were gathered through semi-structured interviews to capture operational realities, pain points, and strategic priorities, and these qualitative insights were validated against technical publications and procedural standards to ensure scientific accuracy.

In addition, technical validation exercises reviewed representative PDX protocols and annotation practices to assess reproducibility risk and data interoperability. The segmentation approach mapped model types, tumor classes, study modalities, implantation methods, applications, and end-user profiles to identify distinct capability requirements and service gaps. Throughout the process, quality assurance checks were performed to confirm the provenance of cited methods and the currency of regulatory and ethical guidance referenced.

Limitations include sensitivity to ongoing technological developments and evolving policy landscapes, which is why the research emphasizes adaptive recommendations and encourages periodic reassessment. The methodological framework supports reproducible updating and can be tailored to incorporate new primary data or targeted deep dives on specific tumor types or geographies.

Consolidated insights synthesizing scientific, operational and policy factors that will determine the near-term trajectory and translational success of PDX initiatives

In summary, patient-derived xenograft models remain a cornerstone of translational oncology when they are embedded within rigorous molecular characterization pipelines and managed through resilient operational systems. Scientific advances in single-cell analytics, immune humanization, and orthotopic modeling are enhancing the translational fidelity of PDX platforms, while supply chain pressures and changing procurement economics are prompting strategic shifts toward domestic capability building and regional partnerships.

To realize the full potential of PDX approaches, stakeholders must balance the need for high biological relevance with considerations of throughput, cost, and reproducibility. Standardized protocols, interoperable data practices, and collaborative models that distribute infrastructure burdens will be central to this effort. Ultimately, the organizations that align technical excellence with strategic supply chain planning and clear translational pathways will be best positioned to convert preclinical insights into clinical success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Patient-Derived Xenograft/PDX Model Market, by Type

  • 8.1. Mice Models
  • 8.2. Rat Models

9. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 9.1. Gastrointestinal
  • 9.2. Gynecological
  • 9.3. Hematological
  • 9.4. Respiratory
  • 9.5. Urological

10. Patient-Derived Xenograft/PDX Model Market, by Study Type

  • 10.1. Ex-vivo
  • 10.2. In-vitro
  • 10.3. In-vivo

11. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

  • 11.1. Heterotopic
  • 11.2. Orthotopic
  • 11.3. Subcutaneous

12. Patient-Derived Xenograft/PDX Model Market, by Application

  • 12.1. Basic Cancer Research
  • 12.2. Biomarker Discovery
  • 12.3. Genomic & Molecular Studies
  • 12.4. Personalized Medicine
  • 12.5. Preclinical Drug Evaluation
  • 12.6. Tumor Microenvironment Analysis

13. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 13.1. Academic Research Institutes
  • 13.2. Cancer Research Centers
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Patient-Derived Xenograft/PDX Model Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Patient-Derived Xenograft/PDX Model Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Patient-Derived Xenograft/PDX Model Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Patient-Derived Xenograft/PDX Model Market

18. China Patient-Derived Xenograft/PDX Model Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abnova Corporation
  • 19.6. Altogen Labs
  • 19.7. Biocytogen
  • 19.8. BioDuro LLC
  • 19.9. BioReperia AB
  • 19.10. Certis Oncology Solutions
  • 19.11. Champions Oncology, Inc.
  • 19.12. Charles River Laboratories International, Inc.
  • 19.13. Creative Animodel
  • 19.14. Creative Biolabs
  • 19.15. Crown Bioscience by JSR Corporation
  • 19.16. EPO Berlin-Buch GmbH
  • 19.17. GemPharmatech Co. Ltd.
  • 19.18. Genesis Drug Discovery & Development
  • 19.19. Hera Biolabs
  • 19.20. HOIST Co.,Ltd.
  • 19.21. InnoSer
  • 19.22. Inotiv, Inc.
  • 19.23. Laboratory Corporation of America Holdings
  • 19.24. LIDE Shanghai Biotech, Ltd
  • 19.25. Mediford Corporation by PHC Holdings Corporation
  • 19.26. Oncodesign Services
  • 19.27. Shanghai ChemPartner
  • 19.28. Shanghai Medicilon Inc.
  • 19.29. TheraIndx Lifesciences Pvt. Ltd.
  • 19.30. Urosphere SAS
  • 19.31. WuXi AppTec Co., Ltd.
  • 19.32. Xentech

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 144. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 172. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)